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STRUCTURED SUMMARY 49 
 50 
AIMS 51 
A systematic review of the literature published in English over 10 years was undertaken in 52 
order to describe the use of electronic healthcare data in the identification of  potential 53 
adverse drug reactions (ADRs) in children. 54 
 55 
METHODS 56 
MEDLINE and EMBASE were searched using MESH headings and text words. Titles, key 57 
words and abstracts were checked for age <18, potential ADRs and electronic healthcare 58 
data.  Information extracted included age, data source, pharmacovigilance method, 59 
medicines and ADRs. Studies were quality assessed. 60 
 61 
RESULTS 62 
From 14,804 titles, 314 had a full text review and 71 were included in the final review. Fifty 63 
were published in North America, 10 in Scandinavia.  Study size ranged from less than 64 
1000 children to more than 10 million. 65 
Sixty per cent of studies used data from one source. Comparative observational studies 66 
were most commonly reported (66.2%) with 15% using passive surveillance.    Electronic 67 
healthcare data set linkage and the quality of the data source were poorly reported. 68 
ADRs were classified using the International Classification of Disease (ICD10). Multi-69 
system reactions were most commonly studied, followed by central nervous system and 70 
mental and behavioural disorders.   Vaccines were most frequently prescribed followed by 71 
corticosteroids, general anaesthetics and antidepressants. 72 
 73 
 74 
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CONCLUSIONS 75 
Electronic healthcare records are increasingly used to detect ADRs in children.  Titles, 76 
keywords or abstracts of papers rarely identified the methodology. Performance against 77 
published guidelines for reporting data linkage studies was poor.  A classification system 78 
to aid consistent definition of study design and improved reporting of key quality issues 79 
would improve pharmacovigilance in children. 80 
 81 
 82 
 83 
 84 
 85 
 86 
 87 
 88 
 89 
 90 
 91 
92 
5 
 
 
Introduction 93 
The therapeutic use of medicines is one of the most significant contributors to adverse 94 
events associated with healthcare[1;2]. The potential for Adverse Drug Reactions (ADRs) 95 
in children is high[3] with a range of factors contributing to this vulnerability including the 96 
physiological changes which take place from those of birth to late adolescence, the lack of 97 
evidence-based information regarding the safety and/or efficacy of medicine for paediatric 98 
use and the high volume of off-label and unlicensed prescribing[4-6] . 99 
 100 
The overall incidence of ADRs in hospitalised children has been reported in two systematic 101 
reviews (2001 and 2009) to be 9.5% and 10.9% respectively. Admissions to hospital due 102 
to ADRs were estimated to be 1.8% to 2.1%; of which up to 39.3% were considered life 103 
threatening. The overall incidence in children attending out-patient clinics was 1.0% to 104 
1.5%  105 
In 2001, a systematic review of ADRs in hospitalised children reported the overall 106 
incidence as 9.53%, the overall rate of paediatric hospital admissions due to ADRs as 107 
2.09%, of which 39.3% were life-threatening and the overall incidence in children attending 108 
out-patient clinics was 1.46%[7];. A review in 2009 of prospective studies and safety 109 
alerts[8]. reported the overall incidence of ADRs in hospitalised children as 10.9% and 110 
1.0% in those attending as out-patients while the rate of hospital admissions due to ADRs 111 
was 1.8%.  112 
 A qualitative review in 2010 of information about adverse drug reactions reported in 113 
children highlighted the potential in 2010 of data collected in national databases for 114 
detecting information about previously unknown ADRs[9].  115 
 116 
Smyth in a systematic literature review of adverse drug reactions in children[10] noted in 117 
2012 additional information on how ADRs in children were reportedmethods for ADR 118 
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detection. Combinations of methods were used in the majority (58/102) including drawing 119 
on case records,  and computerised records, attendance at ward rounds and interviewing 120 
patients but a large proportion (31/102) relied only on case note review. Lopez-Gonzalez 121 
(2009) reporting a systematic review in 2009 onhighlighted the determinants of under-122 
reporting of ADRs demonstrated  123 
that whilethrough spontaneous reporting of adverse events and that spontaneous reports 124 
identified a small proportion of the total, but, nevertheless, it continued to play an important 125 
role in their detection[11]. 126 
 127 
Given the high numbers of ADR reported  in children, some of which are life-threatening 128 
and many of which are preventable, efficient methods of identifying ADRs as part of 129 
routine practice are a critical part of improving patient care[12;13].   There are ‘no gold 130 
standards’ for identifying adverse drug reactions in health systems and a range of 131 
approaches have been developed[6]. The use of electronic healthcare records in the 132 
detection of adverse reactions has increasingly appeared to have potential and the use of 133 
ADR detection in adults has been reported[14]. Electronic healthcare records include a 134 
wide range of data source types, from administrative data systems, dispensing data sets, 135 
disease registries and spontaneous reports where collated routinely. 136 
 137 
In order to describe the use of routinely collected electronic healthcare data in the 138 
identification of potential ADRs in children we undertook a systematic review of the 139 
literature published in English over 10 years.    140 
 141 
Methods 142 
Literature Search 143 
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A systematic review of literatureLiterature published in English was identified in EMBASE 144 
and MEDLINE databases between 1999 and 2010. The database search was 145 
supplemented by searching reference lists of retrieved reviews. The initial search was 146 
conducted in September 2009 and updated in January 2010. 147 
 148 
Inclusion and Exclusion Criteria 149 
Papers were considered eligible for inclusion in the review if they referred to ADRs in 150 
children (aged 0-18 years). A broad definition of ADR was used in this review, accepting 151 
papers reporting the investigation of any potentially adverse clinical event (e.g. specific 152 
clinical signs, symptoms or diagnoses, or a clinical event such as an admission to hospital 153 
or a visit to a physician) associated with a medicinal product, including vaccines. Only 154 
papers reporting the use of routinely collected electronic healthcare data were included.  155 
“Routine” was defined as either a) systems that were part of the day to day recording of 156 
clinical care (e.g. medical records, prescribing, administrative data and complaints); or b) 157 
special data collections where information collection was a well established part of clinical 158 
practice (e.g. specialist registries, incident reporting systems, post-marketing surveillance).  159 
 160 
Papers were excluded if they reported a mix of adults and children but did not separate the 161 
results by age. Adverse reactions or complications occurring as a result of surgical or other 162 
physical procedures, medicine withdrawal, dietary treatment and supplementation and 163 
other non-drug therapy interventions were excluded. We did not include intended or 164 
accidental poisoning/overdose or papers concerned with adverse reactions following in 165 
utero drug exposure.  Papers containing insufficient information about the data sources or 166 
definition of ADRs were also excluded.  167 
 168 
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A search strategy was developed, piloted and refined in collaboration with an experienced 169 
clinical librarian. Subject headings and subheadings from the MeSH vocabulary for 170 
MEDLINE were combined using Boolean terminology with a wide-range of free-text terms 171 
covering four domains: adverse reactions, drug therapy, observational studies and 172 
paediatric populations (see Appendix 1, Supplemental Digital Content). The text term 173 
‘randomised’ and MeSH term ‘pregnancy’ were used to remove randomised controlled 174 
studies and reports regarding drugs prescribed during pregnancy. The results were limited 175 
to “all children (0 to 18 years)”. A similar search strategy was applied in EMBASE.  176 
 177 
Box 1 Pharmacovigilance Methods: WHO classification (adapted4) 178 
 179 
Duplicate publications were removed. Titles and abstracts of the remaining papers were 180 
examined against the inclusion/exclusion criteria by the three reviewers. This initial 181 
screening was conducted using a conservative approach: full-text papers were retrieved if  182 
their titles/abstracts appeared to meet the eligibility criteria or if the decision could not be 183 
made based on the titles and abstracts alone. Assessment of the full texts of each 184 
retrieved paper was undertaken independently by two reviewers using the same criteria 185 
(percentage agreement 81%).  Any disagreements about inclusion were resolved through 186 
discussion (19% of papers). Assessment by a third reviewer to resolve disagreements was 187 
not required.  188 
 189 
Data extraction 190 
Data extraction was carried out by two reviewers independently using a specifically 191 
designed and pilotedextraction form.  Information extracted included age, data source, 192 
pharmacovigilance method, medicines and ADRs. Particular attention was paid to the 193 
quality of reporting the data source and ADRs. A simple checklist was adapted from 194 
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guidelines for reporting data linkage studies and selection of databases for 195 
pharmacoepidemiology[15;16].  It included the following key quality issues: ethics review, 196 
data entry procedures, data quality assurance, data linkage methods and quality 197 
assurance, denominator information and completeness of exposure and outcome data.  198 
 199 
Box 1 Pharmacovigilance Methods: WHO classification (adapted) [6] 200 
 201 
The findings of the review were summarised narratively and key characteristics of the 202 
studies tabulated.  Pharmacovigilance methods were categorised as: passive surveillance, 203 
active surveillance or comparative observational studies[6] as shown in Box 1.  The 204 
classification of data sources is summarised in Table 1.  Information about the size and 205 
population coverage was tabulated and summarised graphically. Medicines used in the  206 
studies were classified according to the British National Formulary (BNF) categories.  If 207 
more than three classes of medication were reported in a single study, “various drug 208 
groups” was recorded.  ADRs were classified using the International Classification of  209 
Diseases (ICD-10).  If more than three ICD classes were reported, the ADRs were 210 
classified as “multisystem”. 211 
 212 
Table 1 Classification of data sources reported in the included studies. 213 
Results  214 
Included studies 215 
From a total of 14,804 titles retrieved by the initial electronic search strategy, 314 studies 216 
were identified for full text review. Of these, 243 papers were excluded because they did 217 
not meet the inclusion criteria or provide adequate information about data sources and 218 
ADRs.  Seventy-one papers were included in the final review (Figure 1). 219 
 220 
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Figure 1 PRISMA Flow Diagram of study selection process 221 
Characteristics of included studies 222 
The main characteristics of the papers are summarised in Appendix Table E1 223 
(Supplemental Digital Content)Table 2. The number of published studies grew rapidly 224 
since 1999 with one third of the papers (n=23; 32.4%) being published within the last two 225 
years of the review. Research was dominated by North American countries with 46 226 
(64.8%) of the studies carried out in the USA and 4 in Canada and one based in both 227 
countries. Scandinavia (Sweden, Denmark, Finland) contributed 10 (14.1%) and the UK, 4 228 
papers (5.6%). Age ranged from birth to 18 years, with 5 papers focusing on neonates 229 
(first 28 days of life) exclusively (7.0%). 230 
Pharmacovigilance methods  231 
A range of pharmacovigilance methods were observed with 6 studies adopting more than 232 
one methodological approach. Comparative observational methods were the most 233 
commonly reported (n=47, 66.2%), with 15 (21.1%) reporting passive surveillance 234 
methods and only 3 (4.0%) reporting active surveillance using routine healthcare data.   235 
 236 
The predominant study design within comparative observational methodology was the 237 
cohort study (n=38; 53.5%). The remaining studies used case-control (n=5; 7%), cross-238 
sectional (n=1) or a combination of designs (n=3; 4.0%).  239 
 240 
Passive surveillance methods, in many cases, used national Adverse Event Reporting 241 
Schemes including some specific to the medication type, such as vaccines. Most studies 242 
adopted descriptive epidemiological methods, reporting the frequency of various potential  243 
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ADRs. Some used information from prescribing or dispensing data to estimate the size of 244 
the “at risk” population thereby allowing event rates to be approximated.  Data mining 245 
methods were applied to identify potential ADR signals. 246 
 247 
In the studies reporting active surveillance methods, registers, as part of routine care, were 248 
kept for all patients taking specific medicines and ADR information was sought proactively 249 
by linkage to other healthcare data or by proactive follow up and recording of ADRs in the 250 
register. 251 
Data sources  252 
A total of 68 different data sources were identified in the 71 studies which met the inclusion 253 
criteria (Appendix Table E1 E2 Supplemental Digital Content). The majority of studies 254 
(n=42; 59.1%) used data from a single data source, such as a financial reimbursement 255 
system (n=14; 19.7%), hospital database (n=11; 15.5%), or spontaneous reporting system 256 
(n=12; 16.9%). 257 
 258 
Studies based on more than one data source (n=29; 40.9%) often included the use of 259 
registries, financial reimbursement systems and spontaneous reporting systems. 260 
 261 
More than half of the studies which used multiple data sources used data linkage (n=15; 262 
51.2%), 10 (n=10; 34.5%) studies used unlinked data and in the remaining 4 (n=4; 13.8%) 263 
studies it could not be ascertained from the reported methods whether the data sources 264 
were linked. Where no formal linkage was undertaken, the multiple datasets were used to 265 
describe potential ecological associations or to provide estimates of the exposed 266 
population to accompany ADR reports in another data source.  267 
 268 
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Most of the 68 different data sources reported in the included studies were representative 269 
at a single country level (n=46; 67.6%); 11 (n=11; 16.2%) were representative at regional 270 
level or above.   With regard to the size of the data sources, information on 32 out of 68 271 
(47.1%) were not reported within the included published paper and had to be obtained 272 
through extra searching.  Data sources were reported either based on the population 273 
covered (n=54; 79.4%) or the number of events reported per year/within the study period 274 
(n=15; 22.1%) (Figure 2 and Supplemental Digital Content Table E1). 275 
 276 
 277 
Figure 2 Size of the 68 data sources reported by population covered or the number of 278 
events reported per year/within the study period 279 
M=Millions *2 data sources did not report size 280 
 281 
Quality of reporting data sources 282 
The amount of information and level of detail reported for the data source varied greatly 283 
across studies (see Figure 3). Ethics permissions were well reported. Most studies used 284 
unconsented data (e.g. without individual patient consent for the data to be used in 285 
research in general or specifically in a given research project). Data entry methods were 286 
poorly reported in most of the studies with many reliant on data collection as part of routine 287 
clinical care but little information about who entered the data. Very few commented on the 288 
completeness or quality assurance of the source data. Validation against clinical registries 289 
or other sources were noted by some authors, in the main relating to well established 290 
administrative and healthcare databases used regularly for research (such as GPRD, 291 
Kaiser Permante, Dutch national datasets). 292 
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 293 
Linkage methods were poorly described and the limitations were rarely quantified. None of 294 
the studies reported on whether deterministic or probabilistic matching was undertaken. 295 
The completeness and accuracy of the linkage identifiers or the validation checks 296 
undertaken to ensure robust linkage were also poorly reported. 297 
 298 
Some important limitations were noted by the reviewers, particularly with the passive 299 
surveillance methods reliant on potential ADRs being reported by various professional 300 
groups and patients to a central registry. The relationship between reporting and various 301 
factors including publicity in relation to an ADR were acknowledged.  The lack of a robust 302 
denominator (how many were exposed) was recognised but largely complete pharmacy 303 
dispensing data in some countries allowed this limitation to be overcome.  ADR recording 304 
in routine data was noted, by many authors, to be poor. The application of disease or ADR  305 
 306 
 307 
definitions and coding of conditions was not uniform within and between studies. The 308 
impact this had on generalisability was recognised.  The need for high quality information 309 
about the date of onset of symptoms in relation to the timing of medicine use was also 310 
noted as a limitation by some.  However, there was a consistent recognition of the 311 
importance of electronic healthcare data as a mechanism to follow up large numbers of 312 
medicine users over long periods of time in a real life care setting. This was considered to 313 
be critical for both good governance of the introduction of new medicines for long term 314 
ADR monitoring and for rare ADR detection. 315 
 316 
Figure 3 Summary of the quality assessment  317 
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 318 
ADRs and therapeutic groups of medicines studied in routine healthcare data 319 
The definition of ADR varied between studies with some including all ADRs and adverse 320 
events, and others restricted to serious, life threatening ADRs or specific clinical 321 
outcomes. The studies reported the investigation of a spectrum of potential ADRs involving 322 
different organ systems. In twenty three (32.4%) studies electronic healthcare data were 323 
used to identify potential ADRs across multiple organ systems (see Table 2). Where 324 
studies focused on three or less ICD classes, the most commonly studied were 325 
mental/behavioural disorders (n=10; 14.1%), central nervous system (10; 14.1%) and 326 
digestive system (n=8; 11.3%), (Table 2). One study reported on abnormal laboratory 327 
results.  328 
 329 
Almost 40% of included studies (n=27) were concerned with investigation of potential 330 
ADRs to vaccines (Figure 4). Antidepressants, antipsychotics and other central nervous 331 
system (CNS) drugs were the second most commonly studied therapeutic class (n=13; 332 
18.3%), followed by corticosteroids (n=7; 9.9%), antibiotics and antivirals (n=7; 9.9%) and 333 
general anaesthetics (n=7; 9.9%).  334 
 335 
Figure 4 Therapeutic groups of medicines studied for potential ADRs in routine electronic 336 
healthcare data  337 
 338 
 339 
Table 2 The key characteristics of the included studies. 340 
 341 
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Discussion 342 
In this systematic review, we identified many pharmacovigilance studies in children using 343 
routine electronic healthcare data.  The number of studies increased over the period of the 344 
review and reflected pharmacovigilance activity in many countries in particular North 345 
America. A wide variety of routine electronic healthcare data sets were used. Traditional, 346 
passive ADR reporting databases were used in 17% of the studies but there was also 347 
substantial evidence of the use of single and linked administrative datasets and specialist 348 
registries to detect ADRs.  Methods such as data mining and comparative observational 349 
studies were applied to a wide range of data sources but signal generation, as an early 350 
alert to potential ADRs, still very much relied on passive reporting to ADR registries such 351 
as the UK Yellow Card Scheme or the US Vaccine Adverse Event reporting System.  The 352 
Erice Manifesto of 2006 for Global Reform of the Safety of Medicines in Patient Care 353 
documented various challenges in developing pharmacovigilance from a largely reactive 354 
activity to proactive study of drug safety in routine clinical practice. It highlighted the need 355 
to develop new ways of collecting, analysing and communicating information in relation to 356 
drug safety and the importance of quality assured research in databases and registries. 357 
Despite WHO making the case for integrated pharmacovigilance as an essential 358 
component of public health programmes that use medicines, we found little reporting of the 359 
integration of active surveillance using routine administrative, healthcare or laboratory data 360 
to generate potential signals[88].    361 
 362 
Search Strategy 363 
In this review we used a sensitive search strategy and systematically reviewed a large 364 
number of titles and abstracts seeking relevant studies; approaches similar to other 365 
reviews in this area[10;89]. Using search terms, either MeSH headings or as free text, 366 
proved of limited value in focusing a search strategy without losing key references. Smyth 367 
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et al[10], in their systematic review of ADRs in children, also retrieved a large number of 368 
titles from which the majority were excluded. In general, studies did not clearly identify that 369 
they were studying ADRs. Sometimes ADRs were reported only as one of a number of 370 
outcomes, but even where ADR detection was the main focus, studies were often poorly 371 
identified as such. The methodological approach of the study was also rarely reported 372 
clearly in the title, keywords or abstract.  Guidance for the reporting of other study designs 373 
now clearly states the importance of including a statement about study design in the title to 374 
improve the ability to retrieve relevant evidence from bibliographic databases. The 375 
CONSORT statement promotes the inclusion of the study design in the title for randomised 376 
controlled trials[90] and similar guidance on titles and key word coding would benefit the 377 
reporting of studies of ADRs.  378 
 379 
ADR detection methods 380 
The WHO classifies ADR detection methods based on data collection procedures as well 381 
as study methodology (Box 1)[6]. For example, passive surveillance is described both  382 
in terms of the recording of the data – through spontaneous reporting, and in terms of the 383 
analytical approaches of data mining that might be applied to such data. The practical 384 
application of this classification is, however, challenging as technology and methodology 385 
has evolved. Traditional passive ADR recording systems, where ADRs are submitted to a 386 
central register by prescribers, health professionals or patients were increasingly 387 
interrogated proactively to provide early warning signals of ADRs employing various 388 
methods including data mining techniques or linkage to other data sources to establish the  389 
numbers exposed to a drug. Routinely collected administrative healthcare data were not 390 
being used to proactively seek signals for potential ADRs but rather to test hypotheses of 391 
associations between medicines and symptoms or diseases using traditional  392 
epidemiological observational study designs. The WHO classification mixes methods for 393 
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collecting the data with methods for interrogating the data that no longer well categorise 394 
the way researchers are approaching ADR studies. In this review we utilised the high level 395 
methodologies to categorise approaches: passive surveillance, active surveillance and 396 
comparative observational studies.  This recognises that for each methodological 397 
approach there are a wide range of potential data collection methods and analytical 398 
methods that could be applied. 399 
 400 
Quality Assessment 401 
We undertook quality assessment of the included studies using criteria focusing on the 402 
assessment of whether key methodological aspects were reported clearly. Smyth et al[10], 403 
who were unable to find a validated quality assessment tool, similarly developed a quality  404 
assessment form for their review.  Despite restricting our review to studies with sufficient 405 
information about the data sources and methods used, we still found substantial variation 406 
in the detail and quality of reporting.  There was particularly limited information recorded 407 
about the robustness and validity of the datasets providing data. Michel et al[91], reviewing 408 
methods for assessing the nature and scale of harm caused by the health system, 409 
previously drew attention to the importance of the reliability of healthcare data and the 410 
limitations of health records as a source of information about ADRs and emphasised in 411 
particular the need for information about the completeness of data in medical records.  412 
 413 
Where more than one dataset was linked, the methods for linkage and validation of the  414 
linkage process was generally not described. Bohensky et al[16] recently published 415 
guidelines for the reporting of data linkage studies. The studies we included in this review  416 
performed poorly against such criteria. The ethical use of the data was considered and 417 
most studies included a statement about the ethical review process. The included studies 418 
did, however, undergo a variety of different ethical review processes ranging from 419 
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statements that "ethical review was not required” because data were “anonymous" through 420 
to full ethics committee review and approval for each use of a dataset. Box 2 summarises 421 
recommendations for authors reporting pharmacovigilance studies using routine electronic 422 
healthcare data. 423 
 424 
Strengths and limitations of the review 425 
We report a large systematic review of the methods and electronic healthcare data 426 
sources used for ADR detection in children but there were a number of limitations to our 427 
review.  We undertook a sensitive search but this resulted in a large number of titles and 428 
abstracts for review.  As a result, only one researcher reviewed each title. To minimise  429 
inconsistencies, we used detailed inclusion and exclusion criteria and adopted a 430 
conservative approach of including studies for full text review where uncertainty existed.  431 
We know that other studies of ADRs in children using electronic routine healthcare data 432 
have been published but were not identified in our review often because they were 433 
reported as the association between a specific medicine and a disease or symptom and as 434 
a result were not clearly identifiable as a study of ADRs.  Twenty three studies were 435 
excluded because there was insufficient information provided about the data sources for 436 
the purpose of this review. 437 
 438 
Post marketing surveillance using electronic healthcare data 439 
Surveillance of drugs in the post marketing phase since the Thalidomide disaster in the 440 
1960s[92] has depended largely on analyses of spontaneous reports to identify new 441 
adverse drug events and of observational healthcare studies to confirm or refute 442 
suspected adverse events. The withdrawal of Rofecoxib in 2004 reinforced again the 443 
importance of adverse drug event monitoring to identify as early as possible serious 444 
unwanted adverse effects of drugs[93]. 445 
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 446 
The potential of using routine electronic healthcare data to identify adverse events has 447 
increasingly been recognised and during the period of this review significant progress has 448 
been made in North America and Europe. Curtis et al described in 2012 how the Food and 449 
Drug Administration (FDA) established the Sentinel System a nationwide network of 450 
databases in the United States of America and the use of the Mini-Sentinel distributed data 451 
system to inform and facilitate the development of active surveillance for monitoring the 452 
use and safety of medicinal products[94]. The European Commission likewise funded a 453 
project, EU-ADR, to demonstrate the feasibility of combining datasets from various 454 
countries to identify unwanted adverse drug events and has developed advanced 455 
techniques for harmonisation of data [95]. 456 
 457 
The use of electronic healthcare data in the study of potential Adverse Drug Reactions is 458 
increasingly developed in America and Europe but as serious adverse drug reactions are 459 
usually identified initially in small numbers, the pooling and analysis of larger electronic 460 
healthcare data sets will facilitate their early detection. The United Kingdom has 461 
contributed General Practice data to the EU-ADR project while many administrative 462 
systems, dispensing data sets, disease registries and spontaneous reporting systems are  463 
also well developed and could increase the potential of electronic healthcare data sets in 464 
the identification of previously unidentified ADRs.   465 
 466 
Conclusion 467 
This systematic literature review identified a large number of resources worldwide used to 468 
study a wide range of medicines and potential ADRs in children. The increasing utility of 469 
routine electronic healthcare datasets for pharmacovigilance in children was evident and 470 
this growing and important health protection activity could be enhanced: by consistent 471 
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reporting of studies to improve the identification, interpretation and generalisability of the 472 
evidence base.   Titles, key words and abstracts rarely identified the methodology.   A 473 
clear classification system should be developed  to aid consistent definition of ADR 474 
detection methods.   Published guidelines should be used for reporting data linkage 475 
studies.   Reporting of key quality issues should be improved.   There is a wealth of 476 
electronic healthcare data and realisation of its potential could contribute significantly to 477 
pharmacovigilance as part of a wider pooling process. 478 
 479 
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